secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-07-08T23:59:59+00:00
Accession:  0001213900-25-061939
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX publishes Phase 1b/2a BX004 data in Nature Communications; shows 500-fold bacterial reduction
--------------------------------------------------------------------------------

- BX004 achieved 2.7 log10 (~500-fold) greater bacterial reduction vs placebo in CF patients with chronic P. aeruginosa infections.
- No bacterial resistance to BX004 emerged during the trial, addressing a key limitation of antibiotics.
- Phase 2b trial of BX004 initiated; topline results expected Q1 2026.
- BX004 was safe and well-tolerated with no treatment-related safety events across all patients and dose levels.
- Therapeutic phages were detected at infection site up to one week after end of therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025061939/0001213900-25-061939-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025061939/ea0248257-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-061939

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer